2.—(1) Schedule 2 to the Misuse of Drugs Act 1971 (which specifies the drugs which are subject to control under that Act) is amended as follows.
(2) In Part 2 (Class B drugs)—
(a)after paragraph 1(b), insert—
“(c)[2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1, 2, 3–de]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone.
3–Dimethylheptyl–11–hydroxyhexahydrocannabinol.
[9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate.
9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[c]chromen–1–ol.
Nabilone.
Any compound structurally derived from 3–(1–naphthoyl)indole or 1H–indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.
Any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
Any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.”;
(b)in paragraph 2A, after “derivative” insert “or of a substance for the time being specified in paragraph 1(c) of this Part of this Schedule.”.
(3) In Part 3 (Class C drugs)—
(a)in paragraph 1(a), after “Flurazepam”, insert “Gamma–butyrolactone”;
(b)in paragraph 1(b)—
(i)before “4–Androstene–3,17–dione”, insert—
“5α–Androstane–3,17–diol.
Androst-4-ene-3,17-diol.
1–Androstenediol.
1–Androstenedione”;
(ii)after “4–Androstene–3,17–dione”, insert “5–Androstenedione.”;
(iii)after “Boldenone.”, insert “Boldione.”;
(iv)after “Bolmantalate.”, insert “1,4–Butanediol.”;
(v)after “Clostebol.”, insert—
“Danazol.
Desoxymethyltestosterone”;
(vi)after “Furazabol.”, insert—
“Gestrinone.
3–Hydroxy–5α–androstan–17–one.”;
(vii)after “Nandrolone.”, insert “19–Norandrostenedione.”;
(viii)after “19–Nor–5–Androstene–3,17–diol”, insert “19–Norandrosterone.”;
(ix)after “Norethandrolone.”, insert—
“19–Noretiocholanolone.
Oripavine.”;
(x)after “Propetandrol.”, insert “Prostanozol.”;
(xi)after “Testosterone.”, insert “Tetrahydrogestrinone.”;
(c)after paragraph 1(c), insert—
“(ca)1–benzylpiperazine or any compound structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways—
(i)by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;
(ii)by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups.”;
(d)in paragraph 1(e), after “Somatropin.”, insert “Zeranol.” and “Zilpaterol.”.